This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ADMP Adamis Pharmaceuticals (ADMP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Adamis Pharmaceuticals Stock (NASDAQ:ADMP) 30 days 90 days 365 days Advanced Chart Remove Ads Get Adamis Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.77▼$3.9952-Week Range N/AVolume119,800 shsAverage Volume811,695 shsMarket Capitalization$7.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Read More… Remove Ads Receive ADMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMP Stock News HeadlinesQuantum Computing (NASDAQ:QUBT) Stock Quotes, Forecast and News SummaryNovember 15, 2024 | benzinga.comDMK Pharmaceuticals Corp DMKNovember 8, 2023 | morningstar.com$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.April 2, 2025 | Stansberry Research (Ad)Adamis changes name to DMK Pharmaceuticals, ticker to DMKSeptember 7, 2023 | msn.comAdamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic FocusSeptember 7, 2023 | finance.yahoo.comAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 21, 2023 | finanznachrichten.deAdamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 21, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Closing of $8.0 Million Public OfferingAugust 4, 2023 | finance.yahoo.comSee More Headlines ADMP Stock Analysis - Frequently Asked Questions How were Adamis Pharmaceuticals' earnings last quarter? Adamis Pharmaceuticals Co. (NASDAQ:ADMP) posted its earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) earnings per share for the quarter, missing the consensus estimate of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative net margin of 502.73% and a negative trailing twelve-month return on equity of 420.53%. When did Adamis Pharmaceuticals' stock split? Adamis Pharmaceuticals shares reverse split on Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Adamis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adamis Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and FuelCell Energy (FCEL). Company Calendar Last Earnings3/31/2022Today4/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolNASDAQ:ADMP CIK887247 Webwww.adamispharmaceuticals.com Phone(858) 997-2400FaxN/AEmployees11Year Founded2006Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,480,000.00 Net Margins-502.73% Pretax Margin-471.80% Return on Equity-420.53% Return on Assets-256.87% Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.19 Sales & Book Value Annual Sales$4.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.26) per share Price / BookN/AMiscellaneous Outstanding Shares9,360,000Free Float9,237,000Market Cap$7.26 million OptionableOptionable Beta1.27 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ADMP) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adamis Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adamis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.